KFAS
MLYS icon

Keating Financial Advisory Services’s Mineralys Therapeutics MLYS Stock Holding History

Keating Financial Advisory Services’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1K Hold
226
– – ﹤0.01% 1451
2026
Q1 		$6.12K Buy
+226
New +$6.63K ﹤0.01% 1333

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Keating Financial Advisory Services's MLYS Position: Q2 2026 in Review

Keating Financial Advisory Services held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 226 shares worth $6.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1451.

Keating Financial Advisory Services first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.12K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Keating Financial Advisory Services held 226 shares of Mineralys Therapeutics worth $6.1K as of Q2 2026.
  • Keating Financial Advisory Services left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1451 holding.
  • Keating Financial Advisory Services first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Mineralys Therapeutics position peaked at $6.12K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.